PMID- 30024553
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20240329
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 29
DP  - 2018 Jul
TI  - Zhenwu decoction for chronic heart failure: Protocol for a systematic review and 
      meta-analysis.
PG  - e11559
LID - 10.1097/MD.0000000000011559 [doi]
LID - e11559
AB  - BACKGROUND: Chronic heart failure (CHF), not only a severe personal healthy 
      problem but also a social financial burden, has become a global health concern. 
      Zhenwu decoction (ZWD) has been widely adopted to clinical practice for patients 
      with CHF. It is necessary to update the researches to reevaluate the efficacy and 
      safety of ZWD to provide the up-to-date evidence for CHF management. Therefore, 
      we provide a protocol of systematic review regarding ZWD for CHF. METHODS: The 
      aim of this study was to retrieve papers on the topic of ZWD treatment for CHF in 
      the electrical databases, including PubMed, Cochrane Library, EMBASE, Chinese 
      Biomedical database (CBM), Chinese National Knowledge Infrastructure (CNKI), 
      Wanfang database, and Chinese Science and Technology Periodical database (VIP). 
      The included literatures are those delivered from the time when the databases 
      were established to May 2018. The therapeutic effects based on the mortality and 
      the New York Heart Association (NYHA) function classification will be marked as 
      the primary outcomes. We will use RevMan V.5.3 software to calculate the data 
      synthesis as well as to perform meta-analysis if the results are appropriate. 
      RESULTS: The literature will provide a high-quality synthesis of current evidence 
      of ZWD for CHF from various comprehensive assessment, including mortality, NYHA 
      function classification, left ventricular ejection fraction, 6-minute walk test 
      (6MWT), life quality, and adverse events. CONCLUSION: The systematic review will 
      provide up-to-date evidence to assess ZWD treatment effect for patient with CHF. 
      PROSPERO REGISTRATION NUMBER: PROSPERO CRD42018083813.
FAU - Tang, Qi
AU  - Tang Q
AD  - Guangzhou University of Chinese Medicine, Guangzhou Department of Emergency, 
      Foshan Hospital of TCM, Affiliated Hospital of Guangzhou University of Chinese 
      Medicine, Foshan, China.
FAU - Wang, Yuanping
AU  - Wang Y
FAU - Li, Kuangyi
AU  - Li K
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
MH  - Quality of Life
MH  - Survival Rate
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Ventricular Function, Left/drug effects
MH  - Walk Test
PMC - PMC6086473
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/07/20 06:00
MHDA- 2018/07/31 06:00
PMCR- 2018/07/20
CRDT- 2018/07/20 06:00
PHST- 2018/07/20 06:00 [entrez]
PHST- 2018/07/20 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2018/07/20 00:00 [pmc-release]
AID - 00005792-201807200-00060 [pii]
AID - MD-D-18-04364 [pii]
AID - 10.1097/MD.0000000000011559 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(29):e11559. doi: 10.1097/MD.0000000000011559.